Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
367
datasets available to search
ShareScore release 0.9.0
Dataset results
367 results for “Ibrutinib”
A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)
ClinicalTrials.gov study NCT03053440. IPD Sharing: YES. Countries: 12. Publications: 6.
A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
ClinicalTrials.gov study NCT02703272. IPD Sharing: Not stated. Countries: 20. Publications: 2.
A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies
ClinicalTrials.gov study NCT02329847. IPD Sharing: Not stated. Countries: 6. Publications: 2.
A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL
ClinicalTrials.gov study NCT02514083. IPD Sharing: NO. Countries: 1. Publications: 1.
Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma
ClinicalTrials.gov study NCT02242097. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing
ClinicalTrials.gov study NCT02604511. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
ClinicalTrials.gov study NCT02581930. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia
ClinicalTrials.gov study NCT03225716. IPD Sharing: NO. Countries: 1. Publications: 2.
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
ClinicalTrials.gov study NCT03702725. IPD Sharing: NO. Countries: 1. Publications: 19.
Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
ClinicalTrials.gov study NCT02315768. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma
ClinicalTrials.gov study NCT02532257. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
ClinicalTrials.gov study NCT02446236. IPD Sharing: Not stated. Countries: 1. Publications: 54.
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma
ClinicalTrials.gov study NCT02927964. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
ClinicalTrials.gov study NCT02599324. IPD Sharing: YES. Countries: 4. Publications: 1.
Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
ClinicalTrials.gov study NCT02824029. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)
ClinicalTrials.gov study NCT03474679. IPD Sharing: Not stated. Countries: 1. Publications: 2.
PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
ClinicalTrials.gov study NCT01589302. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation
ClinicalTrials.gov study NCT02420912. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation
ClinicalTrials.gov study NCT03121534. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
ClinicalTrials.gov study NCT02477696. IPD Sharing: YES. Countries: 15. Publications: 6.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.